Evidence map›Paper›PMID 34172097›Full record

Observational studyAdvances in rheumatology (London, England)2021

Cardiovascular risk comorbidities in rheumatoid arthritis patients and the use of anti-rheumatic drugs: a cross-sectional real-life study.

Gustavo Nogueira Schincariol Vicente, Ivânio Alves Pereira, Gláucio Ricardo Werner de Castro, Licia Maria Henrique da Mota, Ana Paula Carnieletto, Dhara Giovanna Santin de Souza, Fabiana Oenning da Gama, Ana Beatriz Vargas Santos, Cleandro Pires de Albuquerque, Manoel Barros Bértolo and 8 more

Open access · diamondAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Advances in rheumatology (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Colchicine for the primary prevention of cardiovascular events.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Article
  3. Article
  4. Observational
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 1 country.

Gustavo Nogueira Schincariol VicenteUniversidade do Sul de Santa Catarina- UNISUL, Florianópolis, SC, Brazil. gustavo_schincariol@hotmail.com.ORCID 0000-0002-4569-5753
Ivânio Alves PereiraUniversidade do Sul de Santa Catarina- UNISUL, Florianópolis, SC, Brazil.
Gláucio Ricardo Werner de CastroUniversidade do Sul de Santa Catarina- UNISUL, Florianópolis, SC, Brazil.
Licia Maria Henrique da MotaHospital Universitário de Brasília, Universidade de Brasília, Brasília, DF, Brazil.
Ana Paula CarnielettoUniversidade do Sul de Santa Catarina- UNISUL, Florianópolis, SC, Brazil.
Dhara Giovanna Santin de SouzaUniversidade do Sul de Santa Catarina- UNISUL, Florianópolis, SC, Brazil.
Fabiana Oenning da GamaUniversidade do Sul de Santa Catarina- UNISUL, Florianópolis, SC, Brazil.
Ana Beatriz Vargas SantosUniversidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Cleandro Pires de AlbuquerqueHospital Universitário de Brasília, Universidade de Brasília, Brasília, DF, Brazil.
Manoel Barros BértoloFaculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brazil.
Paulo Louzada JúniorUniversidade de São Paulo, Ribeirão Preto, SP, Brazil.
Rina Dalva Neubarth GiorgiInstituto de Assistência Médica ao Servidor Público Estadual, Hospital do Servidor Público Estadual de São Paulo, São Paulo, SP, Brazil.
Sebastião Cezar RadominskiUniversidade Federal do Paraná, Curitiba, PR, Brazil.
Maria Fernanda Brandão Resende GuimarãesHospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Karina Rossi BonfiglioliFaculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
Maria de Fátima Lobato da Cunha SaumaFaculdade de Medicina, Universidade Federal do Pará, Belém, PA, Brazil.
Claiton Viegas BrenolUniversidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Geraldo da Rocha Castelar PinheiroUniversidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Universidade do Sul de Santa Catarina · BRUniversidade de Brasília · BRUniversidade do Estado do Rio de Janeiro · BRHospital das Clínicas da Universidade Federal de Minas Gerais · BRHospital do Servidor Público Estadual · BRUniversidade de Ribeirão Preto · BRUniversidade de São Paulo · BRUniversidade Estadual de Campinas (UNICAMP) · BRUniversidade Federal do Pará · BRUniversidade Federal do Paraná · BRUniversidade Federal do Rio Grande do Sul · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRheumatoid arthritis (RA) is a common autoimmune systemic inflammatory disease. In addition to joint involvement, RA patients frequently have other comorbidities, such as cardiovascular diseases. Drugs used for RA treatment may increase or decrease the risk of a cardiovascular event. This study aims to analyze cardiovascular risk comorbidities in patients with RA and the correlation with the use of anti-rheumatic drugs.

methodsCross-sectional study conducted based on the real-life rheumatoid arthritis study database - REAL, a prospective observational cohort study. Associations between the use of anti-rheumatic drugs and the presence of comorbidities were represented by their prevalence ratio and evaluated using the Chi-square or Fisher's Exact tests.

resultsWe assessed 1116 patients, 89.4% women, mean age of 55.15 years and predominance of seropositive disease. 63.3% had some cardiovascular comorbidity, predominantly hypertension (49.9%). The use of glucocorticoids was observed in 47.4% of patients and there was a significant tendency of lower use of these drugs in the presence of dyslipidemia (PR: 0.790; p = 0.007). We observed that the presence of cardiovascular comorbidities was associated with higher use of bDMARDs (PR:1.147; p = 0.003).

conclusionsThe presence of cardiovascular risk comorbidities was confirmed to be higher in RA patients. Different treatment strategies using less glucocorticoids in the presence of dyslipidemia and more common use of bDMARDs in patients with cardiovascular comorbidities suggest that rheumatologists are aware of the potential influence of the DMARDs in the risk of cardiovascular event. Reinforcing these results, we highlight the need for a better baseline assessment to guide the choice of anti-rheumatic drugs in RA patients who have comorbidities.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidCardiovascular DiseasesComorbidityCross-Sectional StudiesFemaleHeart Disease Risk FactorsHumansMaleMiddle AgedProspective StudiesAntirheumatic AgentsCardiovascular diseasesRheumatoid arthritisTreatment

Identifiers

PMID34172097
OpenAlexW3175451170

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.